The overarching goal of this research project is to elucidate at a structural and mechanistic level critical features of both normal and pathogenic Notch signal transduction. Prior to activation, Notch is quiescent and resistant to proteolysis, bu ligand binding triggers the "on" state by stimulating proteolytic cleavage of Notch by the ADAM10 (or ADAM17) metalloprotease at a juxtamembrane site immediately external to the membrane. The work proposed here will address key unresolved questions in the Notch field, including: i) how Notch receptors specifically recognize their ligands, and ii) how ADAM10 proteolysis of Notch is achieved and regulated. We propose to address these key questions in signaling by pursuing the following specific aims: 1. Determine the basis for specific binding between Notch receptors and their canonical ligands. In this aim, we will combine structural, biochemical, and cell-based assays to address one of the central unresolved questions in Notch signal transduction: how do Notch receptors recognize their ligands? The top priority will be to solve an X-ray structure of a receptor-ligand complex. I the process of pursuing this highest-impact, long-term objective, we will determine the intrinsic selectivity of various Notch receptors for different Delta-like ligands, as well as determine structures of individual receptor and ligand fragments in isolation and/or in combination with blocking antibodies of potential therapeutic relevance. 2. Determine the basis for catalytic specificity of ADAM-family metalloproteases in ligand- dependent proteolysis of Notch receptors. Top priorities of this aim will be to identify the processing sites of the different Notch isoforms, to elucidate the structure of the full ADAM10 ectodomain, and to determine the role of the ADAM regulatory region on Notch proteolysis by comparing the enzymatic activities of the isolated protease domain and the full ectodomain on Notch-derived substrates. Successful completion of these aims will constitute a major breakthrough in our understanding of this fundamental signaling pathway and the role it plays during normal development and in the pathophysiology of diseases associated with aberrant Notch signaling. By deepening our knowledge about the structural and biochemical foundations underlying ligand engagement and regulated proteolysis, our studies will identify new therapeutic strategies for management of Notch-related human pathologies, which include developmental disorders, neurodegenerative diseases, cardiovascular diseases, and cancer.

Public Health Relevance

Ligand-dependent Notch signaling is important in many disease-related processes, including tumor cell growth/survival, angiogenesis, and the host immune response. Surprisingly little is known about the molecular details of how ligands bind to Notch receptors, and how the binding step leads to the molecular processing of Notch into its active form by an enzyme called ADAM10. This project will perform studies that fill this gap in current knowledge, and in doing so will elucidate key aspects of Notch receptor activation that will identify new ways to target Notch in various human diseases, including neurodegeneration and cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BCMB-W (02))
Program Officer
Knowlton, John R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard Medical School
Schools of Medicine
United States
Zip Code
Tiyanont, Kittichoat; Wales, Thomas E; Siebel, Christian W et al. (2013) Insights into Notch3 activation and inhibition mediated by antibodies directed against its negative regulatory region. J Mol Biol 425:3192-204
Andrawes, Marie Blanke; Xu, Xiang; Liu, Hong et al. (2013) Intrinsic selectivity of Notch 1 for Delta-like 4 over Delta-like 1. J Biol Chem 288:25477-89
Roti, Giovanni; Carlton, Anne; Ross, Kenneth N et al. (2013) Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell 23:390-405
Blacklow, Stephen C (2013) Refining a Jagged edge. Structure 21:2100-1
Choi, Sung Hee; Wales, Thomas E; Nam, Yunsun et al. (2012) Conformational locking upon cooperative assembly of notch transcription complexes. Structure 20:340-9
O'Donovan, Daniel J; Stokes-Rees, Ian; Nam, Yunsun et al. (2012) A grid-enabled web service for low-resolution crystal structure refinement. Acta Crystallogr D Biol Crystallogr 68:261-7
Aster, Jon C; Blacklow, Stephen C; Pear, Warren S (2011) Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223:262-73
Wang, Nicholas J; Sanborn, Zachary; Arnett, Kelly L et al. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 108:17761-6
Calderwood, Michael A; Lee, Sungwook; Holthaus, Amy M et al. (2011) Epstein-Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. Virology 414:19-25
Tiyanont, Kittichoat; Wales, Thomas E; Aste-Amezaga, Miguel et al. (2011) Evidence for increased exposure of the Notch1 metalloprotease cleavage site upon conversion to an activated conformation. Structure 19:546-54

Showing the most recent 10 out of 29 publications